Septerna (NASDAQ:SEPN) Trading Up 8.4% – Time to Buy?

Septerna, Inc. (NASDAQ:SEPN)’s share price traded up 8.4% on Monday . The company traded as high as $26.43 and last traded at $26.31. Approximately 52,213 shares were traded during mid-day trading, a decline of 85% from the average session volume of 337,603 shares. The stock had previously closed at $24.28.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SEPN shares. TD Cowen began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating for the company. JPMorgan Chase & Co. started coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target for the company. Cantor Fitzgerald initiated coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price objective on the stock. Finally, Wells Fargo & Company initiated coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 target price for the company.

Septerna Stock Up 12.7 %

Insider Transactions at Septerna

In other news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the acquisition, the insider now directly owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. This trade represents a 6.34 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.